STRO PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

STRO ▼ -0.29% at T+20d

LONG call ✗ call lost -0.29% · α vs SPY -4.49% · entry $34.58 → $34.48

Next anchor: T+60d in 29d

Last close $28.80 (close Jun 12) · -16.71% from $34.58 entry

Entry anchored
Apr 17, 03:59 PM ET
via Databento tick

T+1d

-0.67%

call -0.67% · α -0.01%

$34.35

settled 8w ago

T+5d

-2.86%

call -2.86% · α -3.78%

$33.59

settled 7w ago

T+20d

-0.29%

call -0.29% · α -4.49%

$34.48

settled 4w ago

T+60d

—

call — · α —

—

in 29d

Price Chart

Loading chart...

Executive Summary

Sutro Biopharma presented promising preclinical data for its next-generation antibody-drug conjugates (ADCs), including STRO-004, STRO-006, and STRO-227, demonstrating robust antitumor activity and favorable safety profiles. The data reinforce confidence in Sutro’s platform and support upcoming IND filings and clinical readouts in 2026. Partner Astellas also highlighted positive preclinical results for its TROP2-targeted iADC, ASP2998.

Actionable Insight

Traders should monitor upcoming Phase 1 readouts for STRO-004 in mid-2026 and IND filings for STRO-006 and STRO-227 later in the year. Positive clinical translation of preclinical data could drive significant upside, especially given Sutro’s platform differentiation in dual-payload ADCs.

Key Facts

STRO-004 showed strong antitumor activity across TF-expressing solid tumor PDX models at a 5 mg/kg dose, with improved efficacy vs. benchmark ADCs and a high HNSTD of 50 mg/kg, indicating a wide therapeutic window.
STRO-006 demonstrated dose-dependent antitumor activity in NSCLC and head and neck cancers, with IND submission planned for 2026.
STRO-227, a dual-payload ADC targeting PTK7, showed superior efficacy over single-payload ADCs in breast, ovarian, and NSCLC models; IND filing expected late 2026.
Astellas’ TROP2-targeted iADC ASP2998, developed using Sutro’s platform, entered clinical dosing earlier in 2026 and showed potent efficacy and immune activation in preclinical models.

Financial Impact

No direct financial impact disclosed; potential long-term value from clinical advancement and partnership milestones.

pipeline valueR&D trajectorypartner revenue potential

Risk Factors

Preclinical success does not guarantee clinical efficacy.
Development timelines may shift; IND filings and clinical results are subject to regulatory and operational risks.
Competition in the ADC space is intensifying, particularly in TROP2 and PTK7 targets.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3276676

4 reports for STRO

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for STRO — sortable, filterable
	Type				Now
Apr 22, 2026 7w ago	DEFA14A NEUTRAL ★ 3/10	$34.83 $31.13	▼ −10.62%	▼ −15.26%	$28.80 (−17.31%)
Apr 19, 2026 8w ago	Press Release BULLISH ★ 7/10	$34.58 $34.48	▼ −0.29%	▼ −4.49%	$28.80 (−16.71%)
Mar 23, 2026 11w ago	S-3 BEARISH ★ 6/10	$23.57 $35.53	▼ −50.74%	▼ −41.84%	$28.80 (−22.19%)
Mar 23, 2026 11w ago	Press Release BULLISH ★ 7/10	$23.57 $35.53	▲ +50.74%	▲ +41.84%	$28.80 (+22.19%)

US Market Status

Market Closed — Opens in 4h 16m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access